0000000000587649

AUTHOR

Christina Kramann

showing 4 related works from this author

Effects of multipurpose contact lens solutions on the protein composition of the tear film

2005

Abstract Objectives: To analyze the influence of multipurpose contact lens cleaning solutions on tear proteins. Changes in tear film protein profiles of contact lens wearers who used several marketed brands of multipurpose contact lens care solutions, were assessed by ProteinChip analysis. Methods: Three studies were conducted. Study I was a comparison of Complete and OptiFree multipurpose solutions. Study II was a study with Complete Moisture Plus solution, Study II was a comparison of Renu and Solocare contact lens solutions. Wearers of soft contact lenses were assigned to use the contact lens care solutions for 4 weeks. Non-contact lens wearing patients were used as controls. Tear sample…

Malemedicine.medical_specialtyContact LensesTear proteinslaw.inventionlawOphthalmologymedicineHumansContact lens careEye Proteinsbusiness.industryProtein levelGeneral MedicineProtein compositionMiddle AgedRefractive ErrorsContact lensLens (optics)OphthalmologyContact lens solutionsTearsFemaleContact Lens Solutionssense organsContact lens cleaning solutionsbusinessFollow-Up StudiesOptometryContact Lens and Anterior Eye
researchProduct

Is Homelessness a Risk Factor for Eye Disease?

2005

<i>Background:</i> There is general agreement on the presence of a correlation between poverty and impaired health. However, only scarce data are available on whether this also applies to the incidence of eye disease. The present study was carried out to evaluate the prevalence of ocular disease in homeless people in Germany. <i>Methods:</i> 107 homeless people (97 male, 10 female; mean age 49 years, range 18–81 years) treated in specialised social service institutions were investigated prospectively according to a standardised ophthalmological screening protocol. This comprised visual acuity, assessment of pupillary light reaction, intra-ocular pressure, slit lamp e…

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryEye diseaseGeneral MedicineDiabetic retinopathyMacular degenerationmedicine.diseaseeye diseasesSensory SystemsVision disorderOphthalmologyOphthalmologyEpidemiologymedicineCranial nerve diseasesense organsmedicine.symptomRisk factorbusinessOphthalmologica
researchProduct

Effects of intraocular cefotaxime on the human corneal endothelium

2001

Abstract Purpose To ascertain whether 0.4 mL of cefotaxime 0.25% applied intracamerally causes toxic alteration of the human corneal endothelium. Methods In this prospective randomized masked study, 66 patients had cataract extraction using phacoemulsification, a frown incision, and implantation of a poly(methyl methacrylate) intraocular lens. This was followed by intraocular injection of 0.4 mL of cefotaxime 0.25% or balanced salt solution (BSS®). Contact specular microscopy and photography were performed preoperatively and 1 to 4 days and 3 months postoperatively. Results In the cefotaxime group, the mean endothelial cell count was 2729 cells/mm 2 ± 474 (SD) preoperatively, 2520 ± 462 cel…

AdultMalemedicine.medical_specialtyCorneal endotheliumCefotaximeAnterior Chambermedicine.medical_treatmentCell CountIntraocular lensBalanced salt solutionCefotaximeDouble-Blind MethodLens Implantation IntraocularCorneaOphthalmologymedicineHumansProspective StudiesAgedCell SizeAntibacterial agentAged 80 and overEndophthalmitisPhacoemulsificationbusiness.industryEndothelium CornealPhacoemulsificationMiddle AgedSensory SystemsCephalosporinsEndothelial stem cellOphthalmologymedicine.anatomical_structureFemaleSurgerysense organsbusinessmedicine.drugJournal of Cataract and Refractive Surgery
researchProduct

Intravitreal ranibizumab treatment of retinal angiomatous proliferation

2010

. Purpose:  To determine the efficacy of intravitreal injections of ranibizumab in the treatment of retinal angiomatous proliferation (RAP) in neovascular age-related macular degeneration. Methods:  Retrospective, consecutive case series of 26 eyes (26 patients) treated with intravitreal injections of 0.5 mg ranibizumab for RAP. Patients received intravitreal injections at monthly intervals during upload phase for a 3-month period. Results:  Mean visual acuity before treatment was 0.75 ± 0.38logMAR (mean ± SD, n = 26). In the upload phase, mean visual acuity improved 4 weeks after the initial injection to 0.6 ± 0.37logMAR (n = 26) and to 0.53 ± 0.34logMAR (n = 26) 4 weeks after the third mo…

MaleAngiomatosismedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsFoveal thicknessRetinal NeovascularizationAntibodies Monoclonal Humanizedchemistry.chemical_compoundOpticsRanibizumabOphthalmologymedicineHumansMaintenance phaseAgedRetrospective StudiesAged 80 and overbusiness.industryRetinalGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseeye diseasesOphthalmologyTreatment OutcomechemistryIntravitreal InjectionsRetreatmentWet Macular DegenerationFemalesense organsRanibizumabIntravitreal ranibizumabmedicine.symptombusinessTomography Optical Coherencemedicine.drugActa Ophthalmologica
researchProduct